Barrington analyst Michael Petusky lowered the firm’s price target on Merit Medical (MMSI) to $103 from $111 and keeps an Outperform rating on the shares. Merit updated its FY25 guidance given the difficult tariff backdrop and it now sees non-GAAP EPS in a range of $3.29-$3.42, down from $3.58-$3.70, on an unchanged forecast for $1.47B-$1.49B in revenue, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered at Raymond James, weakness an opportunity
- Hold Rating for Merit Medical Systems Amid Tariff Challenges and Limited Upside Potential
- Merit Medical price target lowered to $110 from $111 at Baird
- Merit Medical price target lowered to $106 from $117 at Wells Fargo
- Merit Medical price target lowered to $106 from $112 at Piper Sandler